WEDNESDAY, 15th MAY 2019 COMMENCING 10:30 AM
AT THE COPTHORNE HOTEL CARDIFF, COPTHORNE WAY,
CULVERHOUSE CROSS, CARDIFF CF5 6DH

AGENDA

1. Welcome and introduction

2. Apologies

3. Declarations of interest

4. Minutes of previous meeting

To protect commercial confidentiality the following appraisals will be held in private

5. Appraisal 1: Limited Submission (PAS)
Fingolimod (Gilenya®) a single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of paediatric patients aged 10-17 years of age: for patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI

The meeting will now open to the public for the committee decisions

6. Chairman’s report (verbal update)

7. Appraisal 2: Full Submission
Doxylamine succinate/pyridoxine hydrochloride (Xonvea®) for the treatment of nausea and vomiting of pregnancy in those patients who do not respond to conservative management

8. All Wales COPD Management and Prescribing Guide

9. Antimicrobial Drug Chart

10. National Prescribing Indicators 2018-19 Analysis of Prescribing Data to December 2018

11. Feedback from AWPAG meeting held on 20th March 2019

Date of next meeting – Wednesday, 19th June 2019 in Cardiff

Agenda AWMSG May 2019